Winston & Strawn
Barr Labs' Washington counsel Lawrence Fox resigns from D.C. office of Winston & Strawn at the firm's request. An ongoing investigation indicates that Fox diverted approximately $ 1 mil. from the firm for his own use, Winston & Strawn said. All misuse of funds discovered so far relates to the firm's money and not to any client's, the law firm added. Fox had been an outspoken critic of FDA's handling of Barr's applications. Winston & Strawn said it is currently in discussions with Barr over whether it will continue to represent the generic firm.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth